CBX2 promoted oral squamous cell carcinoma via increasing CEP55/NF-κB/METTL3/SHP2 signaling induced metastasis/proliferation and angiogenesis Authors: Sai Ma, Zhonghua Wang, Chao Li, Zhenli Liu, Xuan Zhang Published: 2025 ABSTRACT AbstractTo investigate the mechanism by which CBX2 promotes oral squamous cell carcinoma (OSCC) by increasing CEP55/NF-κB/METTL3/SHP2 signaling, leading to metastasis, proliferation, and angiogenesis. We employed a comprehensive research approach. Through bioinformatics analysis (GSE153918 dataset), we identified differentially expressed genes (DEGs) and enriched pathways associated with OSCC and CBX2. Immunohistochemistry (IHC) was used to detect CBX2 expression in both tumor and peritumoral tissues from OSCC patients. Twenty-four BALB/c nude mice were divided into three groups and infected with or without CBX2-KD and/or METTL3-OE lentiviruses. Tumor volume and weight changes were observed in nude mice. IHC was performed to observe the protein expression of CBX2 and METTL3. The oral squamous cell carcinoma cell line SCC-25 was divided into six groups and subjected to CBX2 knockdown, NF-κB activation, METTL3 inhibition, METTL3 overexpression, and SHP2 inhibition. Western blot was used to observe the protein expression of CBX2, CEP55, p-NF-κB, METTL3, TGFβ1, p-SHP2, p-PI3K, Slug and Snail. Using Co-Immunoprecipitation (Co-IP) technology, we analyzed the interactions between endogenous CBX2 and CEP55, as well as the interactions between METTL3 and SHP2, and between METTL3 and TGFβ1, in cells. Wound healing, Transwell, and colony formation assays were conducted to observe the migration, invasion, and proliferation of tumor cells. Western blot was used to analyze the protein expression of VEGFA and H1F1α, and tube formation assays was performed to observe the effects on angiogenesis. Bioinformatic analysis revealed the critical role of the CBX2-NF-κB-METTL3-SHP2 pathway in oral squamous cell carcinoma. IHC results showed that CBX2 expression was lower in peritumoral tissues and higher in OSCC tissues. Tumor formation and IHC results in nude mice showed that CBX2 knockdown inhibited tumor growth, and METTL3 overexpression reversed this effect. Western blot results indicated that CBX2 knockdown, NF-κB activation, METTL3 inhibition, METTL3 overexpression, and SHP2 inhibition all upregulated or downregulated downstream signaling molecules. Co-IP experiments indicated that endogenous CBX2 and CEP55 physically interacted in SCC-25 cells, and METTL3 specifically interacted with SHP2 and TGFβ1. Wound healing, Transwell, and colony formation assays showed that CBX2 knockdown, NF-κB activation, METTL3 inhibition, METTL3 overexpression, and SHP2 inhibition all inhibited or promoted tumor cell migration, invasion, and proliferation. Western blot and tube formation assay results showed that CBX2 knockdown, NF-κB activation, METTL3 inhibition, METTL3 overexpression, and SHP2 inhibition all inhibited or promoted angiogenesis. CBX2 promoted oral squamous cell carcinoma via increasing CEP55/NF-κB/METTL3/SHP2 signaling, leading to metastasis, proliferation, and angiogenesis.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-31475-3.Keywords: OSCC, CBX2, Signaling pathway, Molecular mechanismSubject terms: Cancer, Oral cancer Introduction Oral squamous cell carcinoma (oral squamous cell carcinoma, OSCC) is the most common malignant tumor of the head and neck region, ranking 16th globally in terms of incidence. Each year, more than 460,000 new cases are diagnosed, with a 5-year survival rate of less than 50%. OSCC predominantly arises in the tongue, floor of the mouth, and buccal mucosa, critically impairing eating, speech, and appearance. Its aggressive invasiveness and metastatic propensity severely compromise patients’ quality of life1,2. The primary treatment for OSCC involves surgical resection or a combination of surgery and radiotherapy/chemotherapy. However, the complex structure of the head and neck region leads to approximately one-third of patients experiencing recurrence and metastasis after surgery. For patients with advanced stages, once the tumor has spread, surgical options are often limited, and palliative treatment is the main approach. Radiotherapy can have significant side effects, and chemotherapy often leads to drug resistance, resulting in poor prognosis and high mortality rates. There is an urgent need to investigate the mechanisms of invasion and metastasis in OSCC to improve treatment outcomes3,4. As a core component of the Polycomb Repressive Complex 1 (PRC1), chromobox homolog 2(CBX2) epigenetically regulates gene expression, thereby controlling cell proliferation and differentiation. Recent studies have shown that CBX2 expression levels are significantly elevated in various cancers, such as breast, prostate, and colorectal cancer5–7. In some cancers, such as liver cancer, CBX2 expression levels are reduced8. CEP55 (Centrosomal Protein 55) is a centrosomal protein involved in microtubule organization and the cell division process, particularly in the formation and separation of the mitotic spindle9. In certain cancers, the co-expression of CBX2 and CEP55 can significantly enhance the invasive and metastatic capabilities of tumors. For example, in breast and colorectal cancer, the high expression of CBX2 and CEP55 is associated with high invasiveness and low survival rates10,11. Research has shown that CEP55 activates the NF-κB signaling pathway12,13. Therefore, CBX2 can indirectly regulate the NF-κB signaling pathway by modulating CEP55, influencing the survival and proliferation of tumor cells, which is worth investigating. METTL3 (Methyltransferase-like 3) is an m6A methyltransferase, and its interaction with CBX2 may affect the stability and translation of mRNA, further regulating the expression of tumor-related genes14,15. TGFβ1 (Transforming Growth Factor β1) is a multifunctional cytokine involved in the regulation of cell proliferation, differentiation, migration, and apoptosis16. CBX2 may upregulate the expression of TGFβ1, promoting cell proliferation and invasion, and enhancing the malignant phenotype of tumors. SHP2 (Src Homology 2 Domain Containing Phosphatase 2) is a protein tyrosine phosphatase, and its high expression is associated with the invasiveness and metastatic potential of various cancers. It promotes tumor development by activating cell proliferation and survival signaling pathways17. METTL3, an enzyme that catalyzes mRNA methylation, is thought to play a key role in regulating the m6A modification and promoting the expression of TGF-β118. CBX2 may upregulate SHP2 expression, affecting the activation of the Ras/Raf/MEK/ERK and PI3K/Akt signaling pathways19. However, a detailed understanding of the mechanisms by which CBX2 and its regulatory network influence the development of oral squamous cell carcinoma requires further experimental validation and clinical research. Methods Bioinformatics analysis of gene co-expression OSCC dataset GSE153918, downloaded from the GEO database, was subjected to background correction, normalization, and batch effect correction. Differential expression analysis was performed using the limma package, with screening criteria set at |log2 Fold Change| > 1 and p-value < 0.05. The differentially expressed genes were analyzed for GO (Gene Ontology) and KEGG pathway enrichment using the ClusterProfiler package. The correlation between gene variables was analyzed using the Spearman statistical method. Focusing on the key differential gene CBX2, the survival package was used for proportional hazard hypothesis testing and Cox proportional hazard survival regression model was constructed to quantify its clinical prognostic value. Immunohistochemical detection of CBX2 expression in tumor and peritumoral tissues of OSCC patients Five-micron-thick paraffin sections were cut and laid on adhesive slides. The slides were placed in a slide dryer and heated at 65 °C for 30 min to completely melt the paraffin. Subsequently, the slides were deparaffinized in three xylene gradients, each for 10 min, followed by rehydration in a graded series of 100%, 100%, 90%, and 70% absolute ethanol, each for 5 min, and finally washed in water for 2 min. Antigen retrieval was performed using a pH 6.0 (0.01 M) citric acid buffer for 20 min. The tissues were washed three times with PBS, each for 5 min. A primary mouse anti-human CBX2 antibody (e.g., BD company, 1:150 dilution) was applied at an appropriate ratio, and the slides were incubated overnight in a humidified chamber at 4 °C. The next day, the humidified chamber was removed, and the slides were brought to room temperature for 40 min, then washed three times with PBS, each for 5 min. A secondary goat anti-human antibody (e.g., Dako company, neat) was added according to the tissue size, followed by three more PBS washes, each for 5 min. The sections were then stained with DAB (1:50) under a microscope, counterstained with hematoxylin, separated with acid alcohol, and rinsed in running water for 30 min to blue. The sections were dehydrated in a graded series of ethanol and cleared in xylene before being mounted with epoxy resin. Positive results were determined by the presence of brownish-yellow granules in the cytoplasm or nucleus of the cells. Two researchers performed a double-blind reading to determine the expression of CBX2 in tumor and peritumoral tissues. The consent of the participants and their families has been obtained, and the time for collecting tumor specimens is 1/9/2024. Observation of tumor volume and weight changes in nude mice and immunohistochemical analysis of CBX2 and METTL3 protein expression Twenty-four male BALB/c nude mice, aged 6–8 weeks and weighing 22 ± 2 g, were purchased from Henan Sci-Best Biotechnology Co., Ltd. (Permit No.: SCXK (YU): 2020-0005). The mice were housed in an SPF-grade animal facility, maintained at a constant temperature (20–22 °C) and humidity (50–60%). The health status of the nude mice was observed daily, and weight changes were recorded. First, SCC-25 cells were seeded into 6-well plates at a density of approximately 1 × 105 cells per well and cultured until 70–80% confluence. Then, SCC-25 cells were infected with lentiviral solutions of CBX2-NC, CBX2-KD, and METTL3-OE at a concentration of 1 × 108 TU/mL, with 1 mL of viral solution added to each well. The cells were infected for 48 h. After infection, the SCC-25 cells were collected, washed twice with PBS, centrifuged (1000 rpm, 5 minutes), and resuspended in serum-free medium to a cell density of 5 × 106 cells/mL. The 24 nude mice were randomly divided into 3 groups, with 8 mice in each group. A suspension of 0.2 mL (1 × 106 cells) was subcutaneously injected into the right cheek or hind limb of each mouse. The groups were as follows: BALB/c-CBX2-NC group, BALB/c-CBX2-KD group, and BALB/c-CBX2-KD-METTL3-OE group. From the day of injection, the health status and tumor growth of the nude mice were observed daily. The tumor length and width were measured weekly using calipers, and the tumor volume was calculated using the formula (Volume = length × width2 × 0.5). The weight changes of each mouse were also recorded. The experiment lasted for 6 weeks. At the end of the experiment, the nude mice were euthanized by filling the chamber with carbon dioxide at a rate of 30–70% until the mice were immobile and their pupils dilated, after which the chamber was confirmed for 2 minutes to ensure death. Tumor tissues were excised to a thickness of approximately 4–6 μm and fixed in 10% neutral buffered formalin for immunohistochemical analysis to detect CBX2 and METTL3 protein expression. The immunohistochemical steps were the same as described in 1.2. This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Hebei North University (K2024340).All experiments were conducted according to the relevant naming guidelines and regulations, and the authors adhered to the ARRIVE guidelines. Cell grouping and culture The human tongue squamous cell carcinoma cell line SCC-25 was purchased from Procell Life Science & Technology Co., Ltd., Wuhan (Catalog Number: CL-0569). NF-κB activator E1351 and SHP2 inhibitor PHPS1 were purchased from MedChemExpress, USA. The cells were rapidly removed from the frozen state, placed in a 37 °C water bath and gently shaken until completely thawed. The thawed cells were transferred to T25 flasks. The medium was ensured to contain the necessary nutrients and growth factors for cell growth. The cells were cultured to the logarithmic phase and divided into 6 groups, with 1 × 105 cells in each group. NC group had no specific treatment and cells were cultured in DMEM with DMSO for 48 h. In CBX2-KD Group, cells were transfected with CBX2-specific siRNA at a concentration of 50 nM. Each well (6-well plate) was transfected with 2.5 µL of Lipofectamine 3000 reagent. After 48 h, the cells were used for subsequent experiments. In CBX2-KD-E1351 Group, cells were first transfected with 50 nM CBX2-specific siRNA, then 1 µM NF-κB activator E1351 was added. Each well received 2.5 µL of Lipofectamine 3000 reagent and 1 µL of E1351 (dissolved in DMSO). After 48 h of transfection, E1351 was added, and the cells were further treated for 24 h. In CBX2-KD-E1351-STM2457 Group, cells were first transfected with 50 nM CBX2-specific siRNA, then 1 µM NF-κB activator E1351 and 5 µM METTL3 inhibitor STM2457 were added. Each well received 2.5 µL of Lipofectamine 3000 reagent, 1 µL of E1351, and 5 µL of STM2457 (both dissolved in DMSO). After 48 h of transfection, E1351 and STM2457 were added, and the cells were further treated for 24 h. In CBX2-KD-E1351-STM2457-METTL3-OE Group, cells were first co-transfected with 50 nM CBX2-specific siRNA and 1 µg METTL3 overexpression plasmid, then 1 µM NF-κB activator E1351 and 5 µM METTL3 inhibitor STM2457 were added. Each well received 2.5 µL of Lipofectamine 3000 reagent, 1 µL of E1351, and 5 µL of STM2457 (both dissolved in DMSO). After 48 h of transfection, E1351 and STM2457 were added, and the cells were further treated for 24 h. In CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 Group, cells were first co-transfected with 50 nM CBX2-specific siRNA and 1 µg METTL3 overexpression plasmid, then 1 µM NF-κB activator E1351, 5 µM METTL3 inhibitor STM2457, and 1 µM SHP2 inhibitor PHPS1 were added. Each well received 2.5 µL of Lipofectamine 3000 reagent, 1 µL of E1351, 5 µL of STM2457, and 1 µL of PHPS1 (all dissolved in DMSO). After 48 h of transfection, E1351, STM2457, and PHPS1 were added, and the cells were further treated for 24 h. Western blot to observe expression of corresponding proteins Detected the expression of CBX2(Abcam, ab235305), CEP55༈Cell Signaling Technology, #81,693༉, p-NF-κB༈Abcam, ab86299༉, METTL3༈Cell Signaling Technology, #86,132༉, TGFβ1༈Abcam, ab215715༉, p-SHP2༈Abcam, ab278699༉, p-PI3K༈Abcam, ab154598༉, Slug༈Abcam, ab314086༉, Snail༈Abcam, ab216347༉, VEGFA༈Abcam, ab46154༉, and HIF1α༈Abcam, ab51608༉ proteins in SCC-25 cells. First, prepared the protein lysis buffers (RIPA lysis buffer, PMSF, phosphatase inhibitors, and 5× SDS-PAGE buffer), extracted cellular proteins, and performed SDS-PAGE electrophoresis. Selected an appropriate separation gel concentration based on the molecular weights of the proteins (e.g., 10% or 12%), prepared the gel, and ran the electrophoresis until the bromophenol blue dye front reached the bottom. Then transferred the proteins to a PVDF membrane, blocked with blocking solution (non-fat milk and TBST) for 1 h, and incubated with primary antibodies (such as anti-CBX2, anti-CEP55, etc.) overnight at 4 °C. The next day, washed the membrane with TBST, incubated with secondary antibody Goat anti-rabbit IgG H & L ( HRP ) ( Abcam, ab6721 ) at room temperature for 1 h, washed again, and performed chemiluminescent detection using ECL substrate. Analyzed the expression levels of the target proteins using a gel imaging system, compared them with an internal reference protein (such as GAPDH), and calculated the relative expression levels. Scratch assay to observe tumor cell migration Pre-marked the bottom of the well plate with a marker pen in a well shape with horizontal and vertical lines (three lines each), for subsequent observation and photography. When the cell density in a 10 cm culture dish reached 85%-90%, digested and collected the experimental cells following standard procedures, resuspended the cells in 1 ml of complete medium, seeded them into 6-well plates at an appropriate ratio, aiming for an initial cell density of around 75%-80% coverage of the well bottom, and then placed the plate in a CO₂ incubator at 5% CO₂ and 37 °C for cultivation. Observed under a microscope; when the cell density on the bottom of the well reached approximately 90% (about 12–24 h), used a 200 µl pipette tip to gently make a vertical line within each pair of reference lines, perpendicular to the reference lines. Then washed with sterile PBS to thoroughly remove detached cells and replaced with 1% FBS medium. Took photos under a microscope, named and saved the photos according to the scratch positions, and recorded as 0 h. After photography, continued culturing. Took photos again after 48 h, rinsing with PBS each time before photography to ensure no floating dead cells are present. Finally, used ImageJ software to measure the relative migration distances of the cells to assess their migration capabilities. Co-immunoprecipitation (Co-IP) assay to observe protein interactions Prepared the lysis buffer: 25 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 1 mM EDTA, and proteinased inhibitor (Merck Millipore, 539134). Washed SCC-25 cells once with pre-chilled PBS, add 0.5 mL of pre-chilled lysis buffer, incubated on ice for 5 min, then collected the lysate into a centrifuge tube. Sonicated three times in an ice bath (5 s per sonication, with 10-second intervals) to disrupt cells, then centrifuged at 4 °C at 14,000×g for 10 min. Removed the supernatant and determined protein concentration using the BCA method. Mixed 200 µL of lysate (1 mg/mL) with 30 µL of 50% Protein A/G magnetic beads, incubated at 4 °C with rotation for 30–60 min, performed magnetic separation, discarded the magnetic beads, and retained the supernatant. To investigate the interaction between CBX2 and CEP55, anti-CBX2 antibody (Abcam ab235305) and anti-CEP55 antibody (CST #81693) were used as primary antibodies. To investigate the interaction between METTL3 and SHP2, anti-METTL3 antibody (Cell Signaling #86132) and anti-SHP2 antibody (Abcam ab278699) were used as primary antibodies. To investigate the interaction between METTL3 and TGFβ1, anti-METTL3 antibody and anti-TGFβ1 antibody (Abcam ab215715) were used as primary antibodies. For each immunoprecipitation antibody, a negative control was set as Rabbit IgG (#3900 Rabbit mAb IgG XP Isotype Control), and a positive control was set as the input total protein sample (10% of total protein). Incubated 500 µg of pre-purified lysate with 2 µg of primary antibody at 4 °C for 12 h. Added 30 µL of 50% Protein A/G magnetic beads to each tube, incubated at 4 °C for 2 h, and performed immunoprecipitation. Added 500 µL of lysis buffer and repeated washing four times. Added 30 µL of 2× SDS loading buffer, heated at 95 °C for 5 min, performed magnetic separation, collected the supernatant, and immediately proceeded with Western Blot analysis to detect the bound proteins20. Transwell assay to observe SCC-25 cell migration and invasion SCC-25 cells in logarithmic growth phase were digested with trypsin, resuspended in serum-free medium, and adjusted to a cell density of 2 × 10⁵ cells/mL. A 200 µL cell suspension was added to the upper chamber of a Transwell insert coated with Matrigel (diluted 1:8), and the Transwell insert was gently placed into the lower chamber to avoid air bubbles that could affect the experimental results. The lower chamber was filled with 600 µL of medium containing 10% FBS and incubated in a 37 °C, 5% CO₂ incubator for 48 h. After incubation, the chambers were washed twice with PBS, fixed with methanol for 30 min, stained with 0.1% crystal violet for 30–60 min, and washed three times with PBS. The water in the upper chamber was removed with cotton swabs. The PVDF membrane was fixed onto a glass slide, and the number of cells that had migrated to the lower chamber was observed and counted under a microscope. Five random fields of view were selected for counting, and the average value was taken as the final result. Colony formation assay to observe SCC-25 cell proliferation When the cell density in a 10 cm culture dish reached 85%-90%, the cells from each group were digested and collected following standard procedures, centrifuged to pellet, and resuspended in 1 ml DMEM. A 1:99 dilution was prepared by adding 10 µL of the cell suspension to 990 µL of DMEM, thoroughly mixed, and 20 µL of the diluted cell suspension was pipetted into one end of a cell counting slide (allowing natural adsorption to fill the entire well), with three counting wells inoculated for each type of cell. The cell counting slide was placed into a cell counter, set to cell counting mode, and the count was performed and recorded. The average value was used to calculate the cell concentration. Based on the counting results, the cell density was adjusted, and cells were finally inoculated at a density of 3 × 10³ cells per well into pre-warmed complete medium in 6-well plates, with three replicates for each type of cell, and incubated in a 5% CO₂, 37 °C incubator. Under a microscope, when colonies were visibly formed in the plates (usually around 10 days), the complete medium was replaced every three days. The 6-well plates were removed, the medium was discarded, the wells were washed twice with pre-warmed PBS, 1 ml of methanol was added along the inner walls of the wells for fixation for 30 min, and stained with 1% crystal violet staining solution for 15 min. The staining solution was washed off with slow-flowing water, the plates were air-dried, and photographs were taken. The number of colonies was measured using ImageJ software, and the results were recorded and analyzed. Tube formation assay to observe angiogenesis effect Using HUVECs in good growth condition, trypsin digestion was performed, and digestion was terminated with medium. The cells were collected, washed once with PBS, and then centrifuged at 1500 r/min for 5 min. HUVECs were resuspended in medium and counted using a cell counting slide. The cell concentration was adjusted to an appropriate density (e.g., 1 × 10⁴ cells per well). Similarly, SCC-25 cells in good growth condition were digested with trypsin, counted, and the cell concentration was adjusted to an appropriate density (e.g., 1 × 10⁴ cells per well). Co-culture was performed using Transwell inserts. SCC-25 cells were inoculated in the upper chamber of the Transwell insert, and HUVECs were inoculated in the bottom culture plate (lower chamber). The Transwell insert was placed in a culture plate containing appropriate medium and incubated in a 37 °C, 5% CO₂ incubator. After 48 h of co-culture, the Transwell insert was carefully removed, and the medium from the lower chamber (i.e., the supernatant of HUVECs) was collected. In a 96-well plate, 60 µL of Matrigel was added and allowed to solidify for 30 min. A 96-well plate and a box of sterilized 200 µL pipette tips were placed in a refrigerator to cool to a low temperature. Using pre-chilled 200 µL pipette tips, 60 µL of Matrigel was added to the pre-chilled 96-well plate on an ice plate, taking care to avoid bubbles, and the 96-well plate was gently shaken to quickly spread the Matrigel evenly. The 96-well plate with the spread Matrigel was placed in a cell culture incubator for 30 min to allow the liquid Matrigel to solidify. After the Matrigel solidified, 100 µL of cell suspension was added to each well. The 96-well plate was placed in a cell culture incubator for incubation. After 24 h of incubation, the tube formation in the 96-well plate was observed and photographed under a microscope for recording. Statistical analysis Experimental data are expressed as mean ± standard deviation (Mean ± SD). Statistical analysis was performed using SPSS software. One-way ANOVA was used to compare differences among multiple groups. Independent samples t-test was used for two independent variables. p < 0.05 was considered statistically significant. Graphs and charts were created using GraphPad Prism software, with significant difference groups marked with asterisks. **P < 0.01, *P < 0.05. Results Bioinformatics analysis reveals the key role of the CBX2-NF-κB-METTL3-SHP2 pathway in oral squamous cell carcinoma Sample conditions and grouping clustering were visualized using box plots (Fig. 1A) and principal component analysis (Fig. 1B). Differential analysis between the two groups was performed using the limma package, and the results were displayed using a volcano plot (Fig. 1C), leading to the identification of 74 significantly differentially expressed genes, among which CBX2 was confirmed as a significantly upregulated gene (Fig. 1D). GO and KEGG analyses showed that these differentially expressed genes were significantly enriched in multiple biological pathways, particularly in the PI3K-Akt signaling pathway (Fig. 1E-G), JAK-STAT signaling pathway, and mTOR signaling pathway, which are known to be closely related to tumor cell proliferation, survival, and metastasis. GO analysis further revealed significant enrichments in cellular components (such as phosphatidylinositol 3-kinase complexes), molecular functions (such as phosphatidylinositol kinase activity), and biological processes (such as phosphatidylinositol-mediated signaling). Through Spearman correlation analysis, we found positive correlations between CBX2 and CEP55 (Fig. 1H), CEP55 and NF-κB (Fig. 1I), NF-κB and METTL3 (Fig. 1J), and METTL3 and SHP2(PTPN11) (Fig. 1K), suggesting the existence of complex regulatory networks among these molecules. CEP55, as a cell cycle regulatory factor, may play an important role in the invasiveness and metastasis of OSCC, while METTL3, being related to RNA methylation, may influence the biological characteristics of tumor cells. Survival curve analysis showed that patients with high expression of CBX2 had a poor prognosis ( HR = 1.54 ) (Fig. 11). This clinical outcome echoes the molecular conclusion of CBX2 up-regulation in Fig. 1D, which together proves that CBX2 leads to poor prognosis by promoting tumor progression. Bioinformatics analysis reveals the crucial role of the CBX2-NF-κB-METTL3-SHP2 pathway in oral squamous cell carcinoma. (A) Boxplot of sample correction; (B) PCA plot of differential samples; (C) Volcano plot of differential genes; (D) Ordered plot of differential genes; (E) Bar chart of GO enrichment analysis; (F) Bubble plot of KEGG enrichment analysis; (G) Lollipop chart of KEGG enrichment analysis; (H) Scatter plot of CBX2 and CEP55 correlation; (I) Scatter plot of CEP55 and NF-κB correlation; (J) Scatter plot of NF-κB and METTL3 correlation; (K) Scatter plot of METTL3 and SHP2 (PTPN11) correlation; (L) CBX2 expression levels and patient survival analysis. Immunohistochemical results show that CBX2 is less expressed in pericancerous tissue and more expressed in OSCC To investigate the expression differences of CBX2 between peritumoral tissues and OSCC, we conducted immunohistochemical analysis. Immunohistochemical results indicated that the expression levels of CBX2 in human pericancerous tissues were lower, while they were significantly increased in OSCC tissues, with statistically significant differences (Fig. 2A). High expression of CBX2 in OSCC. (A) Immunohistochemical analysis results of CBX2 in OSCC tissues and human peri-tumor tissues, as well as statistical analysis graphs of CBX2 expression levels. N = 32; (Ba) Experimental results graph of tumor formation experiments in nude mice showing tumor volume sizes for BALB/c-CBX2-NC group, BALB/c-CBX2-KD-KD group, and BALB/c-CBX2-KD-METTL3-OE group, as well as statistical analysis chart of tumor volume; (Bb) Immunohistochemical experiment analysis of CBX2 and METTL3 experimental results figures, as well as statistical analysis charts of protein expression levels. N = 8; Data are expressed as mean ± standard deviation; * P < 0.05; ** P < 0.01; nsP > 0.05. Nude mouse tumorigenesis and immunohistochemical results show that CBX2 knockdown inhibits tumor growth, while METTL3 overexpression reverses this effect To investigate the effects of CBX2 knockdown and METTL3 overexpression on tumor, we performed nude mouse tumorigenesis and immunohistochemical analysis. The results of nude mouse tumorigenesis showed that the tumor volume was smaller and the weight was lighter in the BALB/c-CBX2-KD group compared to the BALB/c-CBX2-NC group, with significant differences. There were no significant differences in tumor volume or weight between the BALB/c-CBX2-KD-METTL3-OE group and the BALB/c-CBX2-NC group. However, compared to the BALB/c-CBX2-KD group, the tumor volume increased and the weight became heavier in the BALB/c-CBX2-KD-METTL3-OE group, with significant differences (Fig. 2Ba). Immunohistochemical results from the nude mouse tumor formation experiment revealed significantly reduced CBX2 protein expression in the BALB/c-CBX2-KD group and BALB/c-CBX2-KD-METTL3-OE group compared to the BALB/c-CBX2-NC group. Compared with the BALB/c-CBX2-KD group, CBX2 expression levels in the BALB/c-CBX2-KD-METTL3-OE group showed no significant change. METTL3 protein expression was significantly reduced in the BALB/c-CBX2-KD group compared to the BALB/c-CBX2-NC group. In contrast, METTL3 protein expression was significantly increased in the BALB/c-CBX2-KD-METTL3-OE group compared to the BALB/c-CBX2-KD group. There was no significant change in METTL3 expression levels between the BALB/c-CBX2-KD-METTL3-OE group and the BALB/c-CBX2-NC group (Fig. 2Bb). These results indicate that CBX2 knockout inhibits tumor growth, while METTL3 overexpression reverses this effect. Western blot and co-IP results show that CBX2 knockdown, NF-κB activation, METTL3 inhibition, METTL3 overexpression, and SHP2 inhibition all up- or downregulate downstream signaling molecules To investigate the effects of CBX2, NF-κB, METTL3, and SHP2 on downstream signaling molecules, we conducted Western Blot analysis to examine the expression levels of relative proteins. Compared with the NC group, in the CBX2-KD group where CBX2 was knocked down, the expression levels of CBX2, CEP55, p-NF-κB, METTL3, TGFβ1, and p-SHP2 proteins were significantly reduced. Compared with the CBX2-KD group, after adding an NF-κB agonist to the CBX2-KD-E1351 group, there was no significant difference in the expression levels of CBX2 and CEP55 proteins, but the expression levels of p-NF-κB, METTL3, TGFβ1, and p-SHP2 proteins were significantly increased. Compared with the CBX2-KD-E1351 group, after adding a METTL3 inhibitor to the CBX2-KD-E1351-STM2457 group, there was no significant change in the expression levels of CBX2, CEP55, and p-NF-κB proteins, while the expression levels of METTL3, TGFβ1, and p-SHP2 proteins were significantly decreased. Compared with the CBX2-KD-E1351-STM2457-METTL3-OE group, after overexpressing METTL3 in the CBX2-KD-E1351-STM2457-METTL3-OE group, there was no significant difference in the expression levels of CBX2, CEP55, and p-NF-κB proteins compared to the control group, but the expression levels of METTL3, TGFβ1, and p-SHP2 proteins were significantly increased. Compared with the CBX2-KD-E1351-STM2457-METTL3-OE group, after inhibiting SHP2 in the CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 group, there was no significant change in the expression levels of CBX2, CEP55, p-NF-κB, METTL3, and TGFβ1 proteins, but the expression level of p-SHP2 protein was significantly decreased (Fig. 3A). Western blot and Co-IP results indicate that knockdown of CBX2, activation of NF-κB, inhibition of METTL3, overexpression of METTL3, and Inhibition of SHP2 all upregulate or downregulate downstream signaling molecules. (A) Western Blot analysis of protein bands for CBX2, CEP55, p-NF-κB, METTL3, TGFβ1, and p-SHP2 in the NC group, CBX2-KD group, CBX2-KD-E1351 group, CBX2-KD-E1351-STM2457 group, CBX2-KD-E1351-STM2457-METTL3-OE group, and CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 group, as well as statistical analysis graphs of relative protein expression levels. GAPDH was as a control protein; (B) Western Blot analysis of protein bands for p-PI3K, Slug, and Snail, along with statistical analysis graphs of relative protein expression levels. GAPDH was as the control protein; (C) Statistical analysis chart of the Co-IP experiment analyzing the interaction between endogenous CBX2 and CEP55 in SCC-25 cells. N = 6; Data are expressed as mean ± standard deviation; * P < 0.05; ** P < 0.01; nsP > 0.05. Compared with the NC group, the CBX2-KD group showed significantly reduced expression of p-PI3K, Slug, and Snail proteins after CBX2 knockdown. In the CBX2-KD-E1351 group, NF-κB agonist addition led to significant upregulation of these proteins. Conversely, in the CBX2-KD-E1351-STM2457 group, METTL3 inhibitor administration resulted in marked downregulation. Overexpression of METTL3 in the CBX2-KD-E1351-STM2457-METTL3-OE group further enhanced p-PI3K, Slug, and Snail expression. Finally, inhibition of SHP2 in the CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 group caused significant downregulation of these proteins (Fig. 3B). To clarify the epigenetic function of CBX2, Co-IP experiments showed that endogenous CBX2 physically interacted with CEP55 in SCC-25 cells (Fig. 3C). The above results indicated that knockout of CBX2, activation of NF-κB, inhibition of METTL3, overexpression of METTL3, and inhibition of SHP2 all upregulated or downregulated downstream signaling molecules. Scratch, transwell, and colony formation assays indicate that CBX2 knockdown, NF-κB activation, METTL3 inhibition, METTL3 overexpression, and SHP2 inhibition either inhibit or promote tumor cell migration, invasion, and proliferation To investigate the effects of CBX2, NF-κB, METTL3, and SHP2 on tumor cells, we conducted scratch, Transwell and colony formation experiments. The results of scratch assays showed that after 48 h, compared with the NC group, the distance in the CBX2-KD group was wider, indicating slower cell migration. Compared with the CBX2-KD group, the distance in the CBX2-KD-E1351 group significantly narrowed, indicating faster cell migration. Compared with the CBX2-KD-E1351 group, the distance in the CBX2-KD-E1351-STM2457 group significantly widened, indicating slower cell migration. Compared with the CBX2-KD-E1351-STM2457 group, the distance in the CBX2-KD-E1351-STM2457-METTL3-OE group significantly narrowed, indicating faster cell migration. Compared with the CBX2-KD-E1351-STM2457-METTL3-OE group, the distance in the CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 group significantly widened, indicating slower cell migration (Fig. 4A). Scratch, Transwell, and Colony Formation Experiments Indicate That Knockdown of CBX2, Activation of NF-κB, Inhibition of METTL3, Overexpression of METTL3, and Inhibition of SHP2 All Inhibit or Promote Tumor Cell Migration, Invasion, and Proliferation. (A) Analysis of scratch test results for NC group, CBX2-KD group, CBX2-KD-E1351 group, CBX2-KD-E1351-STM2457 group, CBX2-KD-E1351-STM2457-METTL3-OE group, and CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 group at 0 hours and 48 hours, as well as statistical analysis of scratch distance; (B) Analysis of Transwell experiment for SCC-25 cells, including the experimental results images for cell migration and invasion, as well as statistical analysis charts of the number of migrating and invading cells; (C) Colony formation analysis of the experimental results graph showing the proliferation of SCC-25 cells in experiments, as well as the statistical analysis graph of the number of clone cells. N=6; Data are expressed as mean ± standard deviation; * P < 0.05; ** P < 0.01;nsP > 0.05. The results of the Transwell assay indicated that compared with the NC group, the number of migrating and invading cells in the CBX2-KD group was reduced. Compared with the CBX2-KD group, the number of migrating and invading cells in the CBX2-KD-E1351 group significantly increased. Compared with the CBX2-KD-E1351 group, the number of migrating and invading cells in the CBX2-KD-E1351-STM2457 group significantly decreased. Compared with the CBX2-KD-E1351-STM2457 group, the number of migrating and invading cells in the CBX2-KD-E1351-STM2457-METTL3-OE group significantly increased. Compared with the CBX2-KD-E1351-STM2457-METTL3-OE group, the number of migrating and invading cells in the CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 group significantly decreased (Fig. 4B). The results of colony formation experiment showed that compared with the NC group, the number of clones in the CBX2-KD group decreased. Compared with the CBX2-KD group, the number of clones in the CBX2-KD-E1351 group significantly increased. Compared with the CBX2-KD-E1351 group, the number of clones in the CBX2-KD-E1351-STM2457 group significantly decreased. Compared with the CBX2-KD-E1351-STM2457 group, the number of clones in the CBX2-KD-E1351-STM2457-METTL3-OE group significantly increased. Compared with the CBX2-KD-E1351-STM2457-METTL3-OE group, the number of clones in the CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 group significantly decreased (Fig. 4C). The above results indicated that CBX2 knockout, NF-κB activation, METTL3 inhibition, METTL3 overexpression, and SHP2 inhibition could all suppress or promote the migration, invasion, and proliferation of tumor cells. Western blot and tube formation assays show that CBX2 knockdown, NF-κB activation, METTL3 inhibition, METTL3 overexpression, and SHP2 inhibition either inhibit or romote angiogenesis To investigate the effects of CBX2, NF-κB, METTL3, and SHP2 on angiogenesis, we conducted Western Blot experiments and tube formation assays.Western blot results showed that in the CBX2-KD group compared to the NC group, after knocking down CBX2, the expression of VEGFA and HIF1α proteins decreased significantly. In the CBX2-KD-E1351 group compared to the CBX2-KD group, after adding the NF-κB agonist, the expression of VEGFA and HIF1α proteins increased significantly. In the CBX2-KD-E1351-STM2457 group compared to the CBX2-KD-E1351 group, after adding the METTL3 inhibitor, the expression of VEGFA and HIF1α proteins decreased significantly. In the CBX2-KD-E1351-STM2457-METTL3-OE group compared to the CBX2-KD-E1351-STM2457 group, after overexpressing METTL3, the expression of VEGFA and HIF1α proteins increased significantly. In the CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 group compared to the CBX2-KD-E1351-STM2457-METTL3-OE group, after inhibiting SHP2, the expression of VEGFA and HIF1α proteins decreased significantly (Fig. 5A). Western blot and tubulogenesis experiment results show that knockdown of CBX2, activation of NF-κB, inhibition of METTL3, overexpression of METTL3, and inhibition of SHP2 all inhibit or promote angiogenesis. (A) Western Blot analysis of VEGFA and HIF1α protein bands in the NC group, CBX2-KD group, CBX2-KD-E1351 group, CBX2-KD-E1351-STM2457 group, CBX2-KD-E1351-STM2457-METTL3-OE group, and CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 group, along with statistical analysis graphs of relative protein expression levels. GAPDH are as the control protein; (B) Tubulogenesis analysis of experimental results, including figures showing the formation of tube-like structures and statistical analysis of the number of neovessels per visual field. N=6; Data are expressed as mean ± standard deviation; * P < 0.05; ** P < 0.01;nsP > 0.05. Tube formation assays showed that in the CBX2-KD group compared to the NC group, after knocking down CBX2, the number of tube formations decreased significantly; this inhibited angiogenesis. In the CBX2-KD-E1351 group compared to the CBX2-KD group, after adding the NF-κB agonist, the number of tube formations increased significantly; this promoted angiogenesis. In the CBX2-KD-E1351-STM2457 group compared to the CBX2-KD-E1351 group, after adding the METTL3 inhibitor, the number of tube formations decreased significantly; this inhibited angiogenesis. In the CBX2-KD-E1351-STM2457-METTL3-OE group compared to the CBX2-KD-E1351-STM2457 group, after overexpressing METTL3, the number of tube formations increased significantly; this promoted angiogenesis. In the CBX2-KD-E1351-STM2457-METTL3-OE-PHPS1 group compared to the CBX2-KD-E1351-STM2457-METTL3-OE group, after inhibiting SHP2, the number of tube formations decreased significantly; this inhibited angiogenesis (Fig. 5B).The above results indicated that CBX2 knockout, NF-κB activation, METTL3 inhibition, METTL3 overexpression, and SHP2 inhibition could all inhibit or promote angiogenesis. In summary, this study systematically investigated the main mechanisms by which CBX2 promotes OSCC through enhancing the CEP55/NF-κB/METTL3/SHP2 signaling pathway, thereby inducing metastasis/proliferation and angiogenesis (Fig. 6). Schematic illustration of CBX2 promoting oral squamous cell carcinoma via increasing CEP55/NF-κB/METTL3/SHP2 signaling, inducing metastasis/proliferation, and angiogenesis. Discussion OSCC is a common malignant tumor of the head and neck, with a complex pathogenesis involving multiple molecular pathways and cellular events. In recent years, significant progress has been made in the study of the molecular mechanisms of OSCC, revealing the critical roles of various genes and proteins in tumor initiation, development, and metastasis21. For example, multiple studies have shown that transcription factors, signaling pathway proteins, and epigenetic modifiers play important roles in the progression of OSCC. Transcription factors such as p53, c-Myc, and STAT3, signaling pathways such as PI3K/Akt, MAPK, and NF-κB, and epigenetic modifications such as DNA methylation and histone modification have all been found to be associated with the biological behavior of OSCC22,23. However, most of these studies focus on the effects of single genes or pathways, and the interactions between multiple genes and pathways and their combined effects remain to be further explored. Our study focused on the role of CBX2 and its downstream effector molecules in OSCC. CBX2 is a member of the Polycomb group protein complex. It participates in gene silencing and cell fate determination by binding to H3K27me3-modified histones. Recent studies have found that CBX2 is upregulated in various cancers and can promote tumor cell proliferation, invasion, and migration5–7. In OSCC, the epigenetic regulatory role of CBX2 and its impact on downstream genes have also gradually attracted attention. One study pointed out that high concentrations of furosine exert toxic effects on Sertoli cells by regulating the CEP55/NF-κB/PI3K/Akt/FOXO1/TNF-α pathway13; another study showed that CEP55 activates the NF-κB signaling pathway and promotes the invasiveness of pancreatic cancer cells12. The NF-κB signaling pathway is an important regulator of inflammatory and stress responses within cells, involved in various physiological and pathological processes. Multiple studies have shown that the activation of the NF-κB signaling pathway can promote the growth and invasiveness of various tumor cells24,25. In this study, experimental verification showed that CBX2 promotes the expression of CEP55, thereby activating the NF-κB signaling pathway. First, CBX2 knockdown experiments (CBX2-KD mediated by siRNA) were performed in the OSCC cell line SCC-25. The results showed that after knocking down CBX2, the expression of CEP55 significantly decreased. Further treatment of cells with the NF-κB activator E1351 revealed that E1351 could partially restore the activity of the NF-κB signaling pathway. This indicates that CBX2 promotes the transcriptional expression of CEP55, thereby indirectly activating the NF-κB signaling pathway. This study confirmed through Co-IP experiments that CBX2 directly interacted with CEP55 in OSCC cells. This indicates that CBX2 plays an epigenetic role, possibly stabilizing CEP55 protein or regulating its subcellular localization through direct interaction, thereby activating the NF-κB pathway. This suggests that CBX2 may stabilize CEP55 protein via a non-canonical pathway, providing a new perspective on the dual functions of CBX2 in tumors. NF-κB signaling pathway activation not only affects cellular inflammatory and stress responses, but is also associated with the expression of various epigenetic modifier factors26. We systematically delineated the oncogenic role of CBX2 in OSCC. CBX2 transcriptionally upregulates CEP55 which activates NF-κB signaling, and NF-κB induces METTL3 expression. METTL3 is an important m6A methyltransferase, playing a central role in RNA methylation modification. M6A is one of the most abundant modifications on mRNA, participating in processes such as mRNA stability, translation, and degradation27. In various cancers, high expression of METTL3 has been associated with tumor progression and poor prognosis28,29. Through Western blot validation, this study confirmed that NF-κB activation significantly increases both mRNA and protein levels of METTL3. METTL3, via its m6A methyltransferase activity, can methylate various mRNAs, thereby affecting their stability and translation efficiency. METTL3 was found to promote m6A modification on TGFβ1 and SHP2 mRNAs18,19. TGFβ1 is involved in multiple physiological and pathological processes, including cell proliferation, migration, and EMT16. SHP2 is a non-receptor tyrosine phosphatase involved in PI3K/Akt, MAPK, and JAK/STAT, among others17. These signaling pathways play crucial roles in the progression of OSCC30,31. This study validated this conclusion through correction experiments in SCC-25 cells, indicating that METTL3 promotes m6A modification on SHP2 mRNA, thereby enhancing SHP2 expression. Our Co-IP data demonstrated that METTL3 physically interacted with both SHP2 and TGFβ1. The METTL3-SHP2 complex may facilitate SHP2’s phosphatase activity toward PI3K, explaining rapid PI3K phosphorylation changes upon METTL3 modulation. METTL3-TGFβ1 binding could stabilize TGFβ1 protein or promote its secretion, synergizing with m6A-mediated transcriptional regulation. Disrupting METTL3-SHP2/TGFβ1 interfaces may provide an alternative strategy to METTL3 catalytic inhibition. This scaffolding function parallels findings in breast cancer where METTL3 acts as an adaptor for EGFR signaling, driving cancer progression and metastasis32. In summary, CBX2 promotes CEP55 expression at the transcriptional level, indirectly activating the NF-κB signaling pathway, which in turn promotes METTL3 expression. METTL3, through m6A modification, not only enhances TGFβ1 expression but also promotes SHP2 expression. This series of molecular events plays a crucial role in the progression of OSCC. The enhanced expression of TGFβ1 and SHP2 has a significant impact on the biological behavior of OSCC cells. Specifically, high expression of TGFβ1 can promote the expression of SHP2B3 (SH2B adaptor protein 3), which in turn inhibits the phosphorylation of SHP2 and suppresses the binding of SHP2 to Grb2, further affecting the PI3K phosphorylation level. Research has indicated that TGFβ1 can regulate the PI3K/Akt and JAK2/STAT3 signaling pathways by activating the expression of SHP2B3. Specifically, TGFβ1, through its receptors TGFβR1 and TGFβR2, activates the Smad-dependent signaling pathway, thereby promoting the transcription of the SHP2B3 gene33. SHP2B3 can significantly reduce SHP2 activity by inhibiting its phosphorylation and binding to Grb219,34. These signaling pathways play crucial roles in cell proliferation, migration, and invasion in OSCC. High activity of SHP2 can promote the phosphorylation of PI3K, thereby activating the downstream Akt signaling pathway. Activation of Akt can promote cell proliferation, migration, and invasion, thus facilitating angiogenesis17. In OSCC, the enhanced co-expression of TGFβ1 and SHP2 can significantly impact the cell’s EMT, migration, and invasion capabilities33. EMT is an important mechanism by which tumor cells acquire invasion and metastasis capabilities. It involves changes in cell phenotype, such as the downregulation of the epithelial marker E-cadherin and the upregulation of mesenchymal markers N-cadherin and vimentin35. Multiple studies have shown that TGFβ1 can induce the EMT process in OSCC cells, promoting their invasion and metastasis. High expression of SHP2B3 can inhibit SHP2 activity, thereby affecting the activation of the PI3K/Akt signaling pathway33,35. Activation of Akt can promote the expression of various EMT-inducing transcription factors, such as Snail, Slug, and Twist. These transcription factors can directly or indirectly regulate the expression of EMT-related genes, promoting cell transformation36. This study validated through Western blot that inhibiting SHP2 significantly reduces the expression levels of Snail, Slug, and Twist, thereby inhibiting the EMT process. Furthermore, inhibiting SHP2 can also reduce the migration and invasion capabilities of OSCC cells by inhibiting the PI3K/Akt signaling pathway. This was confirmed through Transwell migration and invasion assays, showing that high expression of SHP2B3 significantly reduces the migration and invasion capabilities of SCC-25 cells. In the progression of OSCC, cell proliferation and angiogenesis are two important biological processes. High expression of TGFβ1 can promote cell proliferation through multiple mechanisms, such as activating the MAPK and PI3K/Akt signaling pathways and promoting cell cycle progression37. Inhibiting SHP2 can reduce cell proliferation by inhibiting the PI3K/Akt signaling pathway. This study validated through clonogenic assays that inhibiting SHP2 reduces the proliferative capacity of SCC-25 cells. Additionally, the expression of TGFβ1 and SHP2B3 significantly impacts angiogenesis. TGFβ1 can promote angiogenesis through various mechanisms, such as enhancing the expression of VEGF (Vascular Endothelial Growth Factor) and promoting endothelial cell migration and tube formation38. This study verified through Western blot and tube formation assays that inhibiting SHP2 suppressed the expression of VEGFA and HIFIα. Furthermore, in co-cultures of SCC-25 cells with HUVECs, inhibiting SHP2 significantly enhanced HUVECs’ tube formation capability, thereby promoting angiogenesis. This study provides a systematic investigation revealing the molecular mechanisms of CBX2 in OSCC. Specifically, CBX2 promotes the expression of CEP55 through transcription, indirectly activating the NF-κB signaling pathway, which in turn promotes the expression of METTL3. METTL3 enhances the stability and translational efficiency of TGFβ1 and SHP2 mRNA through m6A modification, thereby increasing the expression of TGFβ1 and SHP2. TGFβ1 upregulation enhances SHP2B3 expression, which suppresses PI3K/Akt signaling via two mechanisms. Inhibit SHP2 phosphorylation and disrupt SHP2-Grb2 complex formation. Consequently, this axis inhibits EMT, cell migration/invasion, proliferation, and angiogenesis. This finding not only provides new insights into the molecular mechanisms of OSCC, but also lays a theoretical foundation for developing therapeutic strategies targeting CBX2 and related signaling pathways. While our work elucidates CBX2-driven oncogenesis, future studies should address. CBX2 functionality across molecular subtypes of OSCC, and crosstalk between CBX2 and parallel pathways. For example, whether the expression and function of CBX2 are consistent in OSCC cells with different genetic backgrounds, and whether CBX2 affects OSCC progression through other molecular mechanisms. Additionally, the role of METTL3 in m6A modification in different OSCC cells and its regulation of downstream genes warrant further investigation. Moreover, the mechanisms of TGFβ1 and SHP2B3 in OSCC need further validation. The roles of multiple receptors and signaling pathways of TGFβ1 in different cell types may vary, so it is necessary to verify the specific role of the TGFβ1/SHP2B3 axis in more OSCC cell lines and primary cells. Meanwhile, the expression and function of SHP2B3 in different cell types also require further study to clarify its specific regulatory mechanisms in OSCC. Further investigation is needed to understand how CEP55, as a centrosomal protein, is recruited to chromatin by CBX2. The results of this study provide new targets and strategies for OSCC treatment. For example, targeting CBX2 or its downstream molecules, such as CEP55 and METTL3, can inhibit the activation of the NF-κB signaling pathway, thereby reducing the invasion and migration capabilities of OSCC cells. Simultaneously, by inhibiting the expression of TGFβ1 and SHP2B3, the PI3K/Akt signaling pathway can be further affected, thereby inhibiting cell proliferation and angiogenesis. These strategies are expected to become new directions for OSCC treatment, offering more effective treatment options for patients. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Author contributions S.M. and Z.H.W. designed the experiments and wrote the manuscript. C.L., Z.L.L., and X.Z. performed the experiments and collected and processed the data. S.M. reviewed the manuscript and created the figures. Funding Medical Science Research Project of Hebei (20231444). Data availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Competing interests The authors declare no competing interests. Ethical approval This study was approved by the Ethics Committee of the First Affiliated Hospital of Hebei North University. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.